摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-5,6-dimethylfuro[2,3-d]pyrimidine

中文名称
——
中文别名
——
英文名称
4-chloro-5,6-dimethylfuro[2,3-d]pyrimidine
英文别名
——
4-chloro-5,6-dimethylfuro[2,3-d]pyrimidine化学式
CAS
——
化学式
C8H7ClN2O
mdl
MFCD14780456
分子量
182.609
InChiKey
XLQFREWELVXJII-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-chloro-5,6-dimethylfuro[2,3-d]pyrimidine三乙胺 、 sodium hydroxide 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 2.17h, 生成 2-(5,6-dimethylfuro[2,3-d]pyrimidin-4-ylthio)acetic acid
    参考文献:
    名称:
    INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE
    摘要:
    揭示了用于治疗、管理和预防影响骨骼的疾病和紊乱的化合物。特定的化合物是Notum果胶乙酰酶的强效抑制剂,化学结构如下:其中E、G、Y、Z、R1、R2和R3如本文所定义。
    公开号:
    US20120065200A1
  • 作为产物:
    参考文献:
    名称:
    选择性人 STINGA230 激动剂的结构评估及其在巨噬细胞免疫疗法中的应用
    摘要:
    此前,我们鉴定了一种非核苷酸激动剂 BDW568,它可以选择性激活人类 STING A230等位基因。在这里,我们进一步表征了 BDW568 的机制,并强调了其作为遗传佐剂选择性控制工程化巨噬细胞的激活的潜在用途,这些工程化巨噬细胞组成型表达 STING A230 。我们以 1.95 Å 的分辨率获得了与 BDW-OH(活性代谢物)复合的 STING A230 C 端结构域的晶体结构。结构-活性关系研究表明,BDW568 中的所有三个杂环和 S-乙酸酯侧链对于保留活性至关重要。我们证明,BDW568 可以在用表达 STING A230的慢病毒转导的纯化人原代巨噬细胞中强力激活 I 型干扰素信号传导。相比之下,在缺乏 STING A230等位基因的情况下,BDW568 无法刺激健康供体的人原代外周血单核细胞的先天免疫反应。这种高 STING 变异特异性表明 STING A230激动剂在基于巨噬细胞的治疗方法中具有广阔的应用前景。
    DOI:
    10.1021/acsmedchemlett.4c00048
点击查看最新优质反应信息

文献信息

  • NEW BIS-AMIDO PYRIDINES
    申请人:REISER Ulrich
    公开号:US20150057286A1
    公开(公告)日:2015-02-26
    This invention relates to bis-amido pyridines of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R 1 to R 4 have the meanings given in the claims and in the specification.
    这项发明涉及一般式(I)的双酰胺吡啶,其作为SMAC模拟物的用途,含有它们的药物组合物,以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状(如癌症)的药物的用途。R1至R4基团的含义如索赔和说明书中所述。
  • [EN] NEW 6-ALKYNYL PYRIDINE<br/>[FR] NOUVELLE 6-ALCYNYLE PYRIDINE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2015025019A1
    公开(公告)日:2015-02-26
    This invention relates to 6-alkynyl-pyridine of general formula (I), their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R5 have the meanings given in the claims and in the specification.
    这项发明涉及一般式(I)的6-炔基吡啶,它们作为SMAC模拟物的用途,含有它们的药物组合物,以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状(如癌症)的药物的用途。基团R1至R5的含义如索赔和说明书中所述。
  • New 6-Alkynyl Pyridine
    申请人:REISER Ulrich
    公开号:US20150057295A1
    公开(公告)日:2015-02-26
    This invention relates to 6-alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R 1 to R 5 have the meanings given in the claims and in the specification.
    这项发明涉及一般式(I)的6-炔基吡啶,其用作SMAC拟体,含有它们的药物组合物,以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状(如癌症)的药物的用途。R1至R5基团的含义如索赔和说明书中所述。
  • [EN] NEW BIS-AMIDO PYRIDINES<br/>[FR] NOUVEAUX BIS-AMIDO PYRIDINES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2015025018A1
    公开(公告)日:2015-02-26
    This invention relates to bis-amidopyridinesof general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R4 have the meanings given in the claims and in the specification.
    这项发明涉及一般式(I)的双酰胺吡啶类化合物,它们作为SMAC模拟物的用途,含有它们的药物组合物,以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状(如癌症)的药物的用途。基团R1到R4的含义如权利要求和说明书中所述。
  • INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE
    申请人:BARBOSA Joseph
    公开号:US20120065200A1
    公开(公告)日:2012-03-15
    Compounds are disclosed for the treatment, management and prevention of diseases and disorders affecting the bone. Particular compounds are potent inhibitors of Notum Pectinacetylesterase, and are of the formula: wherein E, G, Y, Z, R 1 , R 2 , and R 3 are defined herein.
    揭示了用于治疗、管理和预防影响骨骼的疾病和紊乱的化合物。特定的化合物是Notum果胶乙酰酶的强效抑制剂,化学结构如下:其中E、G、Y、Z、R1、R2和R3如本文所定义。
查看更多

同类化合物

呋喃并[2,3-d]嘧啶-4(1H)-酮 呋喃并[2,3-d]嘧啶-2(3H)-酮 呋喃并[2,3-d]嘧啶 6-苯基呋喃并[2,3-D]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4(3H)-酮 6-(4-甲氧基苯基)呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲氧基苯基)-5-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲基苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(4-氯苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(3-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 5-甲基呋喃并[2,3-d]嘧啶-4-胺 5-溴呋喃并[2,3-D]嘧啶-4-胺 5-氯甲基呋喃并[2,3-d]嘧啶-2,4-二胺 5,6-二甲基呋喃[2,3-d]嘧啶-4-胺 4-氯呋喃[2,3-D]嘧啶 4-氯-6-甲基-呋喃并[2,3-d]嘧啶 4-氨基呋喃并[2,3-D]嘧啶 4,6-二甲基呋喃并[2,3-d]嘧啶 4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺 3-(2-脱氧-beta-D-赤式-呋喃戊糖基)-6-甲基呋喃并[2,3-d]嘧啶-2(3H)-酮 2-甲基硫代呋喃并[2,3-d]嘧啶-6-甲醇 2,4-二氯呋喃并[2,3-d]嘧啶 2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶 5,6-dimethylfuro<2,3-d>pyrimidine-4-carbonitrile 6-(3-aminophenyl)-N-[(1R)-1-phenylethyl]furo[2,3-d]pyrimidin-4-amine 6-(3-aminophenyl)-N-(3-chlorophenyl)furo[2,3-d]pyrimidin-4-amine 2-{[6-(3-aminophenyl)furo[2,3-d]pyrimidin-4-yl]amino}-4-chlorophenol 6-(3-aminophenyl)-N-(4-chloro-2-fluorophenyl)-furo[2,3-d]pyrimidin-4-amine 6-(3-aminophenyl)-N-(3,5-dichlorophenyl)furo[2,3-d]pyrimidin-4-amine 5-{[6-(3-aminophenyl)furo[2,3-d]pyrimidin-4-yl]amino}-2-methylphenol 1-(6-[4-(2-dimethylamino-ethoxy)-phenyl]-5-methyl-2-thiophene-2-yl-furo[2,3-d]pyrimidin-4-ylamino)-3-methyl-pyrrole-2,5-dione (R)-4-(4-((1-phenylethyl)amino)furo[2,3-d]pyrimidin-6-yl)benzonitrile pyrrolidine-1-carboxylic [6-(4-methoxy-phenyl)-furo[2,3-d]pyrimidin-4-yl]-amide N3-[(1-benzyl-1,2,3-triazol-4-yl)methyl]-6-(hex-1-yl)furo[2,3-d]pyrimidine-2-one N3-{[1-(4-chlorophenyl)-1,2,3-triazol-4-yl]methyl}-6-(hex-1-yl)-5-(oct-1-yn-1-yl)furo[2,3-d]pyrimidine-2-one N3-{[1-(2-fluorophenyl)-1,2,3-triazol-4-yl]methyl}-(6-hex-1-yl)furo[2,3-d]pyrimidine-2-one 6-pentyl-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 2-[(5,6-di-(2-furyl)-furo[2,3-d]pyrimidin-4-yl)aminoethoxy]ethanol 6-(4-n-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 2-[(5,6-di-(2-furyl)-furo[2,3-d]pyrimidin-4-yl)amino]butan-1-ol 4-[(5,6-di-(2-furyl)-furo[2,3-d]pyrimidin-4-yl)amino]butan-1-ol 4-chloro-5,6-dimethylfuro[2,3-d]pyrimidine 3-butyl-6-(hexylsulfanylmethyl)furo[2,3-d]pyrimidin-2(3H)-one 3-dodecyl-6-(hexylsulfanylmethyl)furo[2,3-d]pyrimidin-2(3H)-one 6-(hexylsulfanylmethyl)-3-octylfuro[2,3-d]pyrimidin-2(3H)-one 3-decyl-6-(hexylsulfanylmethyl)furo[2,3-d]pyrimidin-2(3H)-one 6-decyl-2-propoxyfuro[2,3-d]pyrimidine